0000000001061252

AUTHOR

Sarah Alexander

showing 2 related works from this author

gcType : a high-quality type strain genome database for microbial phylogenetic and functional research

2020

Abstract Taxonomic and functional research of microorganisms has increasingly relied upon genome-based data and methods. As the depository of the Global Catalogue of Microorganisms (GCM) 10K prokaryotic type strain sequencing project, Global Catalogue of Type Strain (gcType) has published 1049 type strain genomes sequenced by the GCM 10K project which are preserved in global culture collections with a valid published status. Additionally, the information provided through gcType includes >12 000 publicly available type strain genome sequences from GenBank incorporated using quality control criteria and standard data annotation pipelines to form a high-quality reference database. This …

Data AnalysisBACTERIALAcademicSubjects/SCI000100206 medical engineering02 engineering and technologyComputational biologyBiologyGenome03 medical and health sciencesMULTIPLE SEQUENCE ALIGNMENTPhylogeneticsRNA Ribosomal 16SDatabases GeneticGeneticsPROGRAMDatabase IssueALGORITHMPhylogeny030304 developmental biology0303 health sciencesGenomeMultiple sequence alignmentBase SequencePhylogenetic treeResearchGenome databaseBiology and Life SciencesGCM transcription factorsProkaryotic CellsGenBankReference database020602 bioinformatics
researchProduct

Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Pr…

2021

PURPOSE A dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) regimen has been shown to deliver excellent survival for adults with primary mediastinal large B-cell lymphoma (PMLBL) without the use of radiotherapy. No international prospective evaluation of this regimen has previously been reported in children and adolescents. PATIENTS AND METHODS We conducted an international single-arm phase II trial involving patients younger than age 18 years with PMLBL who were to receive six courses of DA-EPOCH-R. The primary end point was event-free survival (EFS). Overall survival and toxicity were also assessed. This trial was regist…

OncologyCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidebusiness.industryORIGINAL REPORTSmedicine.diseaseRegimenOncologyPrednisoneInternal medicinemedicineRituximabDoxorubicinPrimary mediastinal B-cell lymphomabusinessEtoposidemedicine.drugJournal of Clinical Oncology
researchProduct